38 results
F-1
EX-3.1
CNTB
Connect Biopharma Holdings Ltd
26 Feb 21
Registration statement (foreign)
4:56pm
or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms “controlled” and “controlling … Employee”
means each of the Founders and the full-time senior management of the Group Company
“Majority Shareholders”
means the holders of at least
F-1
EX-4.4
CNTB
Connect Biopharma Holdings Ltd
26 Feb 21
Registration statement (foreign)
4:56pm
or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms “controlled … by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, in each case as amended.
“Majority Ordinary
DRS
EX-3.1
CNTB
Connect Biopharma Holdings Ltd
17 Dec 20
Draft registration statement
12:00am
or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms “controlled” and “controlling … Employee”
means each of the Founders and the full-time senior management of the Group Company
“Majority Shareholders”
means the holders of at least
DRS
EX-4.4
CNTB
Connect Biopharma Holdings Ltd
17 Dec 20
Draft registration statement
12:00am
or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms “controlled … by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, in each case as amended.
“Majority Ordinary
20-F
2021 FY
EX-1.1
CNTB
Connect Biopharma Holdings Ltd
31 Mar 22
Annual report (foreign)
4:33pm
the power to control the management or elect a majority of members to the board of directors or equivalent decision-making body of such corporation … a resolution:
a.passed by a simple majority of the votes cast by such Shareholders as, being entitled to do so, vote in person or, where proxies
20-F
EX-2.5
imq 397n7rcue
31 Mar 22
Annual report (foreign)
4:33pm
F-1/A
EX-3.2
xikgpd0bqp m7a876
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-3/A
486emy9a
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
1aewn7sqp
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3/A
6hf6d3drgpk ie72bk
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-1/A
EX-10.2
877w2dl0w79vp w60r7d
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
EX-99.1
oqr83c1 fg
17 May 21
Connect Biopharma Announces First
5:27pm
F-1
EX-10.12
1ys3w8qrqiwi30rb
26 Feb 21
Registration statement (foreign)
4:56pm
6-K
xjr8hq
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
p0qvve8wd 5l6ux
5 Jan 22
Current report (foreign)
5:24pm
F-1/A
EX-10.3
7wasj7
17 Mar 21
Registration statement (foreign) (amended)
6:38am
F-1/A
EX-10.3
4c60kszuxj2f11u5
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
EX-99.2
6u6sxpbut2nuwctzhe09
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.2
8bk0of
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm